General Information:

Id: 2,848
Diseases: Cancer
Diabetes mellitus, type II - [OMIM]
Insulin resistance
Homo sapiens
endometrial cancer cell lines, ECC-1 and BTO:0003041 Ishikawa
article
Reference: Cantrell LA et al.(2010) Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol. Oncol. 116: 92-98 [PMID: 19822355]

Interaction Information:

Comment Obesity and diabetes are strong risk factors that drive the development of type I endometrial cancers.
Formal Description
Interaction-ID: 26242

disease

Obesity

increases_activity of

Comment Obesity and diabetes are strong risk factors that drive the development of type I endometrial cancers.
Formal Description
Interaction-ID: 26243

increases_activity of

Comment The endometrial cancer cell lines, ECC-1 and Ishikawa, were used. Metformin potently inhibited growth in a dose-dependent manner. Treatment with metformin resulted in G1 arrest, induction of apoptosis and decreased hTERT expression.
Formal Description
Interaction-ID: 26244

drug/chemical compound

Metformin

decreases_activity of

Drugbank entries Show/Hide entries for Metformin
Comment The endometrial cancer cell lines, ECC-1 and Ishikawa, were used. Metformin potently inhibited growth in a dose-dependent manner. Treatment with metformin resulted in G1 arrest, induction of apoptosis and decreased hTERT expression.
Formal Description
Interaction-ID: 26245

drug/chemical compound

Metformin

decreases_activity of

Drugbank entries Show/Hide entries for Metformin
Comment The endometrial cancer cell lines, ECC-1 and Ishikawa, were used. Metformin potently inhibited growth in a dose-dependent manner. Treatment with metformin resulted in G1 arrest, induction of apoptosis and decreased hTERT expression.
Formal Description
Interaction-ID: 26246

drug/chemical compound

Metformin

decreases_activity of

process

cell cycle

Drugbank entries Show/Hide entries for Metformin
Comment The endometrial cancer cell lines, ECC-1 and Ishikawa, were used. Metformin potently inhibited growth in a dose-dependent manner. Treatment with metformin resulted in G1 arrest, induction of apoptosis and decreased hTERT expression.
Formal Description
Interaction-ID: 26247

drug/chemical compound

Metformin

increases_activity of

Drugbank entries Show/Hide entries for Metformin
Comment The endometrial cancer cell lines, ECC-1 and Ishikawa, were used. Metformin potently inhibited growth in a dose-dependent manner. Treatment with metformin resulted in G1 arrest, induction of apoptosis and decreased hTERT expression.
Formal Description
Interaction-ID: 26248

drug/chemical compound

Metformin

decreases_expression of

gene/protein

TERT

Drugbank entries Show/Hide entries for Metformin
Comment Treatment with metformin resulted in activation of AMPK, its immediate downstream target, followed by decreased phosphorylation of S6, signifying inhibition of the mTOR pathway. These findings suggest that metformin may function as a novel mTOR inhibitor and emerge as a targeted chemotherapeutic strategy for both the treatment and prevention of endometrial cancer.
Formal Description
Interaction-ID: 26249

drug/chemical compound

Metformin

increases_activity of

complex/PPI

AMPK

Drugbank entries Show/Hide entries for Metformin
Comment Treatment with metformin resulted in activation of AMPK, its immediate downstream target, followed by decreased phosphorylation of S6, signifying inhibition of the mTOR pathway. These findings suggest that metformin may function as a novel mTOR inhibitor and emerge as a targeted chemotherapeutic strategy for both the treatment and prevention of endometrial cancer.
Formal Description
Interaction-ID: 26250

drug/chemical compound

Metformin

decreases_phosphorylation of

gene/protein

RPS6

Drugbank entries Show/Hide entries for Metformin
Comment Treatment with metformin resulted in activation of AMPK, its immediate downstream target, followed by decreased phosphorylation of S6, signifying inhibition of the mTOR pathway. These findings suggest that metformin may function as a novel mTOR inhibitor and emerge as a targeted chemotherapeutic strategy for both the treatment and prevention of endometrial cancer.
Formal Description
Interaction-ID: 26252

drug/chemical compound

Metformin

decreases_activity of

process

TOR signaling

Drugbank entries Show/Hide entries for Metformin